Precision Biosensor

Precision Biosensor FCF Growth

The Year-over-Year Free Cash Flow Growth of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is -10.69 %. In the previous year, Year-over-Year Free Cash Flow Growth was 83.25 % — a change of -112.84% (lower).

FCF Growth

-10.69 %

YoY

-112.84%

Last updated:

Year-over-Year Free Cash Flow Growth of Precision Biosensor is 2025 -10.69 % . Year-over-Year Free Cash Flow Growth of Precision Biosensor was 2024 83.25 % . It decreases by -112.84% lower compared to the previous year.

The Precision Biosensor FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
2.09 KRW
Jan 1, 2019
29.65 KRW
Jan 1, 2020
-203.11 KRW
Jan 1, 2021
-97.49 KRW
Jan 1, 2022
0.05 KRW
Jan 1, 2023
34.35 KRW
Jan 1, 2024
83.25 KRW
Jan 1, 2025
-10.69 KRW
The Precision Biosensor FCF Growth history
YEARFCF GrowthYoY
-10.69 %-112.84%
83.25 %+142.33%
34.35 %+62,795.42%
0.05 %-100.06%
-97.49 %-52.00%
-203.11 %-785.14%
29.65 %+1,315.62%
2.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Year-over-Year Free Cash Flow Growth of Precision Biosensor is -10.69 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Precision Biosensor historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Precision Biosensor

All Key Metrics — Precision Biosensor